home > news > 2009 > august > merck research: simcyp used in discovery to predict phase i pk
Merck research: Simcyp used in Discovery to predict Phase I PK
Date: 17 Aug 2009
A report published in the journal Xenobiotica examines the utility of physiologically-based pharmacokinetic (PBPK) modelling to predict Phase I pharmacokinetics using data available during late-stage lead discovery. The research was undertaken by scientists at Merck Research Laboratories.
Ten compounds, which were anticipated to be eliminated predominantly by CYP metabolism, were selected from Merck’s internal development pipeline. Intrinsic clearance data derived from recombinantly expressed CYPs were used in combination with PBPK modelling to predict the pharmacokinetics of each drug candidate. The results were compared with actual clinical exposure and reasonable agreement was reported between the two sets of data.
The paper, by Gibson et al., is entitled ‘Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling.’
Please click here for a link to the abstract and full text options.